Denis Migliorini has been promoted to Associate Professor

The CRTOH is delighted to announce the appointment of Denis Migliorini as Associate Professor at the Faculty of Medicine of the University of Geneva.

After completing his medical studies in Toulouse and Strasbourg, Denis Migliorini specialized in medical oncology in Geneva, where he obtained his board certification in 2015, before further specializing in neuro-oncology. He holds a DAS from UNIGE in clinical trial management and has served as principal investigator for several early-phase trials focused on cancer immunotherapy.

Between 2016 and 2019, he undertook postdoctoral training at the University of Pennsylvania, where he specialized in synthetic biology and cellular engineering. In 2019, he received the Swiss Bridge Foundation Award for his work aimed at reducing the neurotoxic effects of cellular immunotherapies.

In 2020, he was appointed Assistant Professor and ISREC Chair in Brain Tumor Immunology in the Department of Medicine and at the Translational Research Center in Onco-Hematology of the Faculty of Medicine at the University of Geneva. He is also a member of the Swiss Cancer Center Léman.

His research focuses on the development of new immunotherapies for brain tumors, particularly CAR T-cell therapies, which involve reprogramming patients’ T lymphocytes to target tumor cells. His laboratory develops gene transfer strategies and combination approaches to treat malignant gliomas and other resistant solid tumors.

A physician-scientist at HUG, he leads the neuro-oncology clinic and tumor board while also coordinating the brain tumor biobank. He also heads a laboratory at the Agora Cancer Research Center in Lausanne, where his CAR T-cell therapies are expected to be evaluated from 2027 in an early-phase clinical trial in patients with glioblastoma.

He is an active member of the Swiss and European Societies of Neuro-Oncology (Swiss NOS, EANO) and serves on the editorial board of Neuro-Oncology, a leading journal in the field.

News